407 related articles for article (PubMed ID: 32585295)
21. After 62 years of regulating immunity, dexamethasone meets COVID-19.
Cain DW; Cidlowski JA
Nat Rev Immunol; 2020 Oct; 20(10):587-588. PubMed ID: 32778829
[TBL] [Abstract][Full Text] [Related]
22. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
Luo W; Li YX; Jiang LJ; Chen Q; Wang T; Ye DW
Trends Pharmacol Sci; 2020 Aug; 41(8):531-543. PubMed ID: 32580895
[TBL] [Abstract][Full Text] [Related]
23. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
24. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.
Moutsopoulos HM
Ann Rheum Dis; 2020 Sep; 79(9):1253-1254. PubMed ID: 32345616
[No Abstract] [Full Text] [Related]
25. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
Oscanoa TJ; Romero-Ortuno R; Carvajal A; Savarino A
Int J Antimicrob Agents; 2020 Sep; 56(3):106078. PubMed ID: 32629115
[TBL] [Abstract][Full Text] [Related]
26. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
Miao Y; Fan L; Li JY
Front Immunol; 2020; 11():1445. PubMed ID: 32612616
[No Abstract] [Full Text] [Related]
27. The role of Interleukin 6 inhibitors in therapy of severe COVID-19.
Nasonov E; Samsonov M
Biomed Pharmacother; 2020 Nov; 131():110698. PubMed ID: 32920514
[TBL] [Abstract][Full Text] [Related]
28. A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients.
Roncati L; Ligabue G; Nasillo V; Lusenti B; Gennari W; Fabbiani L; Malagoli C; Gallo G; Giovanella S; Lupi M; Salviato T; Paolini A; Costantini M; Trenti T; Maiorana A
Platelets; 2020 Nov; 31(8):1085-1089. PubMed ID: 32857624
[TBL] [Abstract][Full Text] [Related]
29. Extracorporeal Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm Syndrome.
Napp LC; Bauersachs J
Shock; 2020 Nov; 54(5):700-701. PubMed ID: 32453251
[No Abstract] [Full Text] [Related]
30. Type 3 hypersensitivity in COVID-19 vasculitis.
Roncati L; Ligabue G; Fabbiani L; Malagoli C; Gallo G; Lusenti B; Nasillo V; Manenti A; Maiorana A
Clin Immunol; 2020 Aug; 217():108487. PubMed ID: 32479986
[TBL] [Abstract][Full Text] [Related]
31. Coagulopathy in COVID-19: Focus on vascular thrombotic events.
Shi W; Lv J; Lin L
J Mol Cell Cardiol; 2020 Sep; 146():32-40. PubMed ID: 32681845
[TBL] [Abstract][Full Text] [Related]
32. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome.
Quartuccio L; Semerano L; Benucci M; Boissier MC; De Vita S
Joint Bone Spine; 2020 May; 87(3):191-193. PubMed ID: 32321634
[No Abstract] [Full Text] [Related]
33. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation.
Li S; Zhang Y; Guan Z; Li H; Ye M; Chen X; Shen J; Zhou Y; Shi ZL; Zhou P; Peng K
Signal Transduct Target Ther; 2020 Oct; 5(1):235. PubMed ID: 33037188
[TBL] [Abstract][Full Text] [Related]
34. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
Cao Y; Wei J; Zou L; Jiang T; Wang G; Chen L; Huang L; Meng F; Huang L; Wang N; Zhou X; Luo H; Mao Z; Chen X; Xie J; Liu J; Cheng H; Zhao J; Huang G; Wang W; Zhou J
J Allergy Clin Immunol; 2020 Jul; 146(1):137-146.e3. PubMed ID: 32470486
[TBL] [Abstract][Full Text] [Related]
35. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
Wu D; Yang XO
J Microbiol Immunol Infect; 2020 Jun; 53(3):368-370. PubMed ID: 32205092
[TBL] [Abstract][Full Text] [Related]
36. COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm.
Lee W; Ahn JH; Park HH; Kim HN; Kim H; Yoo Y; Shin H; Hong KS; Jang JG; Park CG; Choi EY; Bae JS; Seo YK
Signal Transduct Target Ther; 2020 Sep; 5(1):186. PubMed ID: 32883951
[TBL] [Abstract][Full Text] [Related]
37. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K
J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973
[No Abstract] [Full Text] [Related]
38. Severe COVID-19: what have we learned with the immunopathogenesis?
Bordallo B; Bellas M; Cortez AF; Vieira M; Pinheiro M
Adv Rheumatol; 2020 Sep; 60(1):50. PubMed ID: 32962761
[TBL] [Abstract][Full Text] [Related]
39. Leukotrienes, a potential target for Covid-19.
Citron F; Perelli L; Deem AK; Genovese G; Viale A
Prostaglandins Leukot Essent Fatty Acids; 2020 Oct; 161():102174. PubMed ID: 32977289
[No Abstract] [Full Text] [Related]
40. A cytokine super cyclone in COVID-19 patients with risk factors: the therapeutic potential of BCG immunization.
Johnson BS; Laloraya M
Cytokine Growth Factor Rev; 2020 Aug; 54():32-42. PubMed ID: 32747157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
